IRONWOOD PHARMACEUTICALS INC

Apraglutide

As previously disclosed in our Quarterly Report on Form 10-Q for the period ended September 30, 2025, filed on November 10, 2025, on October 2, 2025, Ferring International Center S.A., or Ferring, filed a complaint against our wholly-owned subsidiary, VectivBio AG, for trade secret misappropriation and correction of patent inventorship and ownership in the U.S. District Court in the Eastern District of Texas (Case No. 2:25-cv-01001-RWS-RSP), alleging that VectivBio AG misappropriated Ferring’s technology for its own benefit and improperly filed patent applications claiming that technology without reference to Ferring’s inventorship and ownership interests. Ferring sought monetary damages, a declaratory order regarding ownership of certain intellectual property Ferring purported to own, an injunction ordering the transfer or control of such intellectual property, a constructive trust, and certain exemplary damages and costs. As previously disclosed in the Current Report on Form 8-K, filed on December 23, 2025, on December 18, 2025, we, VectivBio AG, and Ferring entered into a settlement agreement and release pursuant to which VectivBio AG and Ferring have settled all claims between the parties arising out of Ferring’s complaint referenced above. In addition, on December 18, 2025, the parties also entered into that certain third amendment, or the Ferring License Amendment, to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio AG) and Ferring. For details regarding the Ferring legal matter, refer to Note 4,Collaboration, License and Other Agreements, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K for further details. The Ferring License Amendment is qualified in its entirety by reference to the complete text of such agreement, a copy of which is filed as Exhibit 10.19.1 hereto. A dismissal of Ferring’s complaint with prejudice was entered in the U.S. District Court in the Eastern District of Texas on December 19, 2025.